Inpharmatica Secures $44M in New Funding To Boost Compute Capacity, Discovery Efforts | GenomeWeb

Structural bioinformatics company Inpharmatica secured £31.25 million ($44 million) in second-round funding led by Dresdner Kleinwort Capital last week.

Additional investors included Abingworth Management, Advent Venture Partners, Gilde Investment, and Vertex Management, as well as 3i Group, Unibio, and GIMV, which contributed to Inpharmatica''s initial funding of 4 million pounds in 1999, and Genentech, which made a strategic investment of an undisclosed amount.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.